EssilorLuxottica acquires RetinAI

Published on October 23, 2025
RetinAI’s platform applies artificial intelligence models to support diagnosis and monitoring of disease progression including AMD, glaucoma, and diabetic retinopathy
Continue reading on website
Other news

AAOpt 2025: Diabetes case studies with an eye to the future with Dr Paul Chous | Optometry Times - Clinical News

October 22, 2025
Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.

Study establishes reference data set for GA lesion progression | Optometry Times - Clinical News

October 23, 2025
Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.